

Review of: "Efficacy of Potassium Competitive Acid Blockers (P-CABs) versus Proton Pump Inhibitors (PPIs) in the First and Second Line Eradication Regimens for *Helicobacter pylori* in Egyptian Patients"

Niccolò Paoletti¹

¹ University of Florence

Potential competing interests: No potential competing interests to declare.

The manuscript entitled 'Efficacy of Potassium Competitive Acid Blockers (P-CABs) versus Proton Pump Inhibitors (PPIs) in the First and Second Line Eradication Regimens for *Helicobacter pylori* in Egyptian Patients' is an interesting and well-written work that compare the efficacy of vonoprazan-based therapy versus proton pump inhibitor (PPI) therapy for the eradication of *H. pylori* infection in treatment-naïve and treatment-experienced Egyptian patients.

There are some missing information and minor errors to be corrected:

- Lack of information on sample size calculation.
- The study was carried out on Egyptian population, but there is no information on the ethnicity of the participants.
- Lack of information on the choice of therapy and posology.
- Comparisons of the treatment regimens of the different studies reported may be useful for a better understanding of the differences in results.
- Was the presence of clarithromycin-resistant *H. pylori* strains detected in the study population?
- Discussions should improve by explaining why no statistical significance was observed, providing supporting articles if available.
- Some of the references used are not in the same format, so they should be carefully checked and standardised: in reference 1 "**Chey, W. D., Leontiadis, G. I., Howden, C. W., & et al. (2017). ACG Clinical Guideline: Treatment of *Helicobacter pylori* Infection. The American Journal of Gastroenterology, 112(2), 212-239. <https://doi.org/10.1038/ajg.2016.563>" delete <https://doi.org/10.1038/ajg.2016.563>, in reference 3 "**Eusebi, L. H., Zagari, R. M., & Bazzoli, F. (2014). Epidemiology of *Helicobacter pylori* infection. *Helicobacter*, 19(Suppl 1), 1-5. <https://doi.org/10.1111/hel.12165>. PMID: 25167938.**" delete <https://doi.org/10.1111/hel.12165>. PMID: 25167938, in reference 13 "**Scott, D. R., Sachs, G., & Marcus, E. A. (2016). The role of acid inhibition in *Helicobacter pylori* eradication. *F1000Research*, 5, F1000 Faculty Rev-1747. <https://doi.org/10.12688/f1000research.8598.1>. PMID: 30023042; PMCID: PMC4957631**" delete <https://doi.org/10.12688/f1000research.8598.1>. PMID: 30023042; PMCID: PMC4957631, in reference 16 "**Saleem, N., & Howden, C. W. (2020). Update on the Management of *Helicobacter pylori* Infection. *Current Treatment Options in Gastroenterology*, 18(3), 476-487. <https://doi.org/10.1007/s11938-020-00300-3>." delete <https://doi.org/10.1007/s11938-020-00300-3>, in reference 18 "**Lyu, Q. J., Pu, Q. H., Zhong, X. F.,******

& Zhang, J. (2019). Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials. BioMed Research International, 2019, Article 9781212. <https://doi.org/10.1155/2019/9781212>" delete
<https://doi.org/10.1155/2019/9781212>, in reference 19 **‘Li, M., Oshima, T., Horikawa, T., Tozawa, K., Tomita, T., Fukui, H., Watari, J., & Miwa, H. (2018). Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter, 23(4), Article e12495. <https://doi.org/10.1111/hel.12495>" delete**
<https://doi.org/10.1111/hel.12495>, in reference 21 **‘Sostek, M. B., Chen, Y., & Andersson, T. (2007). Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. British Journal of Clinical Pharmacology, 64(3), 386-390. <https://doi.org/10.1111/j.1365-2125.2007.02889.x>" delete**
<https://doi.org/10.1111/j.1365-2125.2007.02889.x>, in reference 23 **‘Yamada, S., Kawakami, T., Nakatsugawa, Y., et al. (2016). Usefulness of vonoprazan, a potassium ioncompetitive acid blocker, for primary eradication of Helicobacter pylori. World Journal of Gastrointestinal Pharmacology and Therapeutics, 7(4), 550-555. <https://doi.org/10.4292/wjgpt.v7.i4.550>" delete <https://doi.org/10.4292/wjgpt.v7.i4.550>, in reference 24 **‘Chey, W. D., Mégraud, F., Laine, L., et al. (2022). Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology, 163(3), 608-619. <https://doi.org/10.1053/j.gastro.2022.05.055>" delete <https://doi.org/10.1053/j.gastro.2022.05.055>.****